ABSTRACT
Palmoplantar pustulosis is a variant of psoriasis and a chronic skin disorder in which pruritic pustular eruptions appear on the palms and soles. It is thought to arise from a variety of genetic and environmental factors, is limited in prevalence, and has proven quite difficult to treat. The symptoms it inflicts on those affected are quite debilitating and the treatment landscape is constantly evolving, thus emphasizing the need for updates of the literature as time passes. Current treatments include topical agents, oral therapies, and phototherapy, amongst other treatments. In this systemic review, we explore newer literature from 2015 to 2022 on various treatment regimens for palmoplantar pustulosis. J Drugs Dermatol. 2024;23(8):626-631. doi:10.36849/JDD.doi:10.36849/7612R1.
Subject(s)
Dermatologic Agents , Psoriasis , Humans , Psoriasis/therapy , Psoriasis/diagnosis , Psoriasis/drug therapy , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosage , Phototherapy/methods , Administration, Oral , Administration, Cutaneous , Treatment OutcomeABSTRACT
Erythroderma is characterized by diffuse erythema and scale covering over 90% body surface area that can affect individuals with inflammatory dermatoses such as psoriasis. Complications of erythrodermic psoriasis include infection and cardiovascular compromise. Here we present a case of a 68 year-old man who was hospitalized for erythrodermic psoriasis refractory to multiple immunosuppressive and immunomodulatory therapies, ultimately developing sepsis due to bacteremia and fungemia complicated by infective endocarditis and a mycotic aneurysm. Although the widespread loss of epidermal function in erythroderma increases the risk of infection by opportunistic pathogens, water loss, and electrolyte imbalances, there are very few reported cases of psoriatic erythroderma complicated by fungemia and mycotic aneurysm. Given the high mortality associated with widespread epidermal dysfunction, there is a great need for evidence-based treatment guidelines for psoriatic erythroderma. J Drugs Dermatol. 2024;23(8): doi:10.36849/JDD.7751.
Subject(s)
Aneurysm, Infected , Dermatitis, Exfoliative , Psoriasis , Shock, Septic , Humans , Male , Psoriasis/complications , Psoriasis/drug therapy , Psoriasis/diagnosis , Aged , Dermatitis, Exfoliative/diagnosis , Dermatitis, Exfoliative/etiology , Dermatitis, Exfoliative/therapy , Dermatitis, Exfoliative/drug therapy , Shock, Septic/diagnosis , Shock, Septic/microbiology , Shock, Septic/therapy , Shock, Septic/etiology , Aneurysm, Infected/diagnosis , Aneurysm, Infected/therapy , Aneurysm, Infected/microbiology , Fatal Outcome , Fungemia/diagnosis , Fungemia/drug therapy , Fungemia/microbiology , Fungemia/complications , Practice Guidelines as Topic , Bacteremia/diagnosis , Bacteremia/drug therapy , Bacteremia/complications , Bacteremia/microbiologyABSTRACT
BACKGROUND: Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-world setting are still limited. MATERIALS AND METHODS: We conducted a 104-week monocentric retrospective study on 102 psoriasis patients, all treated with guselkumab for at least 16 weeks. At each visit, we used the Psoriasis Area and Severity Index (PASI): effectiveness endpoints were the percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI compared with baseline. The Kaplan-Meier curve was used to assess the drug survival. RESULTS: At week 16, PASI 90 and PASI 100 were achieved by 49.02% and 32.35% of patients. At week 52, PASI 90 and PASI 100 were achieved by 71.58% and 55.79% of patients. After 2 years, PASI 90 and PASI 100 were achieved by 79.63% and 61.11% of patients. Obese and overweight patients had comparable PASI 90 and PASI 100 responses throughout the study. At week 104, no significant differences were observed between bio-naïve and bio-experienced patients regarding all effectiveness endpoints. No significant safety signals were reported in our study. After 24 months, 91.57% of our cohort was still on treatment with guselkumab. CONCLUSION: Our findings, although limited by the study's retrospective nature, confirm that guselkumab is a safe and effective therapeutic option for a "real-life" cohort of patients with psoriasis. J Drugs Dermatol. 2024;23(8):632-639. doi:10.36849/JDD.7486R1.
Subject(s)
Antibodies, Monoclonal, Humanized , Psoriasis , Severity of Illness Index , Humans , Psoriasis/drug therapy , Psoriasis/diagnosis , Retrospective Studies , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/therapeutic use , Male , Female , Middle Aged , Treatment Outcome , Adult , AgedABSTRACT
BACKGROUND: There is a paucity of data on the treatment of psoriasis in patients with skin of color – a diverse population among whom variations in clinical features and higher quality of life impact have been reported. This single-center, open-label clinical study evaluated the safety and efficacy of secukinumab in the treatment of moderate-to-severe plaque psoriasis in adults with Fitzpatrick skin types IV-VI. METHODS: A total of 20 male and female subjects (ages ≥ 18, BSA ≥10%, PASI Score ≥ 12, IGA ≥ 3) completed this study. The total study duration was 28 weeks. During the treatment period, subjects received secukinumab 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then monthly through week 20. RESULTS: 73% of patients achieved at least 90% improvement in PASI score (PASI90) at week 16 compared to baseline (P=0.0592). There was a statistically significant proportion of patients achieving PASI75, IGA of clear or almost clear, and a change from baseline in DLQI total score at weeks 12, 16, and 24. A statistically significant reduction in IGAxBSA-75 score was achieved between week 16 and baseline. LIMITATIONS: The sample size was small and underpowered to detect statistically significant changes in some endpoints. Furthermore, the study period was interrupted by the COVID-19 pandemic, which contributed to numerous missing data points. CONCLUSION: Secukinumab 300 mg administered monthly was safe, well-tolerated, and efficacious in treating skin of color patients with psoriasis and improving health-related quality of life. Larger studies involving skin of color populations with psoriasis are warranted. J Drugs Dermatol. 2024;23(8):600-606. doi:10.36849/JDD.8128.
Subject(s)
Antibodies, Monoclonal, Humanized , Psoriasis , Quality of Life , Severity of Illness Index , Humans , Psoriasis/drug therapy , Psoriasis/diagnosis , Male , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/administration & dosage , Female , Adult , Middle Aged , Treatment Outcome , Skin Pigmentation/drug effects , Injections, Subcutaneous , Dermatologic Agents/adverse effects , Dermatologic Agents/administration & dosage , Dermatologic Agents/therapeutic use , Aged , COVID-19ABSTRACT
BACKGROUND: Plaque psoriasis is a chronic, relapsing systemic illness that has a significant effect on quality of life. Bimekizumab is the first monoclonal antibody to target both interleukin (IL)-17A and IL-17F, and recently received Food and Drug Administration (FDA) approval for moderate to severe plaque psoriasis. Guidance is necessary regarding the safety of bimekizumab. METHODS: A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the safety of bimekizumab for moderate to severe psoriasis. A panel of 9 dermatologists and 1 rheumatologist with significant expertise in the treatment of psoriasis gathered to review the articles and create consensus statements on this new medication. A modified Delphi process was used to approve each statement, and strength of recommendation was assigned using the Strength of Recommendation Taxonomy criteria. RESULTS: The literature search produced 110 articles that met the criteria. A thorough screening of the studies for relevance to the research question resulted in 15 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 5 consensus statements and recommendations, all of which were given a strength of "A". CONCLUSION: Bimekizumab has a safety profile consistent with other biologics, except for a higher risk of oral candidiasis. Its hepatic safety profile is comparable with other currently FDA-approved biologics for plaque psoriasis. In addition, the data do not support an association of bimekizumab with suicide, and the incidence of inflammatory bowel disease is not greater than the incidence of other IL-17 blockers. J Drugs Dermatol. 2024;23(8):592-599. doi:10.36849/JDD.8246.
Subject(s)
Antibodies, Monoclonal, Humanized , Consensus , Interleukin-17 , Psoriasis , Humans , Psoriasis/drug therapy , Psoriasis/diagnosis , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/therapeutic use , Interleukin-17/antagonists & inhibitors , Interleukin-17/immunology , Dermatologic Agents/adverse effects , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosage , Delphi Technique , Severity of Illness IndexABSTRACT
BACKGROUND: Tildrakizumab is a humanized anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes real-world effectiveness and safety of tildrakizumab through 64 weeks of treatment. METHODS: In this Phase 4, multicenter, uncontrolled, open-label trial (NCT03718299), adults with moderate-to-severe plaque psoriasis received tildrakizumab 100 mg at weeks 0 and 4 and every 12 weeks thereafter through week 52. Effectiveness was assessed from body surface area (BSA) affected and static Physician Global Assessment (sPGA) through week 64 and Psoriasis Area and Severity Index (PASI) through week 52. Adverse events are reported. RESULTS: Of 55 patients enrolled, 45 completed the study and 36 received all doses of tildrakizumab. From baseline to week 64, mean +/- standard deviation BSA decreased by 83.1% (from 14.5 +/- 11.5 to 2.1 +/- 3.6) and sPGA by 67.6% (from 3.2 +/- 0.6 to 1.0 +/- 1.0); sPGA x BSA decreased by 89.6% (from 47.0 +/- 41.5 to 4.6 +/- 9.4; all P<0.001). PASI scores decreased compared to baseline at weeks 4, 16, 28, and 52 (P<0.001). For PASI responses at week 52 compared with baseline, 87.0% achieved greater than or equal to 75% improvement, 56.5% achieved greater than or equal to 90% improvement, and 32.6% achieved 100% improvement. Of 85 treatment-emergent adverse events in 34/55 patients, none were considered related to tildrakizumab treatment. CONCLUSIONS: Tildrakizumab treatment was effective in adult patients with moderate-to-severe plaque psoriasis in real-world settings, with no new safety signals. J Drugs Dermatol. 2024;23(8):612-618. doi:10.36849/JDD.8217.
Subject(s)
Antibodies, Monoclonal, Humanized , Psoriasis , Severity of Illness Index , Humans , Psoriasis/drug therapy , Psoriasis/diagnosis , Female , Male , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Middle Aged , Treatment Outcome , Adult , Interleukin-23 Subunit p19/antagonists & inhibitors , Interleukin-23 Subunit p19/immunology , AgedABSTRACT
Observational studies have shown a strong association between circulating white blood cell counts (WBC) and inflammatory skin diseases such as acne and psoriasis. However, the causal nature of this relationship is unclear. We performed a two-way two-sample Mendelian randomization (MR) analysis to investigate potential causal relationships between leukocytes and inflammatory skin diseases. The circulating white blood cell count, basophil cell count, leukocyte cell count, lymphocyte cell count, eosinophil cell count, and neutrophil cell count data were obtained from the Blood Cell Consortium (BCX). The data for inflammatory skin disorders, including acne, atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis, and seborrheic dermatitis (SD), were obtained from the FinnGen Consortium R10. The primary analysis utilized inverse variance weighting (IVW) along with additional methods such as MR-Egger, weighted mode, and weighted median estimator. To assess heterogeneity among instrument variables, Cochran's Q test was employed, while MR-Egger intercept and MR-PRESSO were used to test for horizontal pleiotropy. IVW demonstrated that an elevated monocyte count was significantly associated with a decreased risk of psoriasis (OR = 0.897, 95% CI: 0.841-0.957, P = 0.001, FDR = 0.016). Additionally, an increased eosinophil count was causally associated with a higher risk of AD (OR = 1.188, 95% CI: 1.093-1.293, P = 0.000, FDR = 0.002). No inverse causal relationship between inflammatory skin disease and circulating white blood cell count was found. In conclusion, this study provides evidence that increased monocyte count is associated with a reduced risk of psoriasis and that there is a causal relationship between increased eosinophil counts and an increased risk of AD. These findings help us understand the potential causal role of specific white blood cell counts in the development of inflammatory skin diseases.
Subject(s)
Mendelian Randomization Analysis , Psoriasis , Humans , Leukocyte Count , Psoriasis/genetics , Psoriasis/blood , Psoriasis/immunology , Psoriasis/diagnosis , Eosinophils/immunologyABSTRACT
Current genome-wide association studies (GWAS) of plasma proteomes provide additional possibilities for finding new drug targets for inflammatory dermatoses. We performed proteome-wide Mendelian randomization (MR) and colocalization analyses to identify novel potential drug targets for inflammatory dermatoses. We performed MR and colocalization analysis using genetic variation as instrumental variables to determine the causal relationship between circulating plasma proteins and inflammatory dermatoses. 5 plasma proteins were found to be causally associated with dermatitis eczematosa, SLE, urticaria and psoriasis using cis-pQTLs as instrumental variables, but not found in AD and LP. 19 candidate genes with high colocalization evidence were identified. These potential drug targets still require more research and rigorous validation in future trials.
Subject(s)
Blood Proteins , Genome-Wide Association Study , Mendelian Randomization Analysis , Proteome , Humans , Mendelian Randomization Analysis/methods , Blood Proteins/genetics , Blood Proteins/analysis , Genetic Predisposition to Disease , Polymorphism, Single Nucleotide , Psoriasis/genetics , Psoriasis/blood , Psoriasis/diagnosis , Quantitative Trait LociSubject(s)
Infant, Premature , Psoriasis , Zinc , Humans , Psoriasis/diagnosis , Zinc/deficiency , Zinc/blood , Diagnosis, Differential , Infant, Newborn , Female , MaleSubject(s)
Psoriasis , Humans , Cross-Sectional Studies , Psoriasis/diagnosis , Psoriasis/complications , Male , Female , Middle Aged , Adult , Sexual Dysfunction, Physiological/diagnosis , Sexual Dysfunction, Physiological/etiology , Sexual Dysfunction, Physiological/epidemiology , Surveys and Questionnaires/statistics & numerical data , Quality of Life , AgedABSTRACT
INTRODUCTION: Melanocytic nevi (MN), warts, seborrheic keratoses (SK), and psoriasis are four common types of skin surface lesions that typically require dermatoscopic examination for definitive diagnosis in clinical dermatology settings. This process is labor-intensive and resource-consuming. Traditional methods for diagnosing skin lesions rely heavily on the subjective judgment of dermatologists, leading to issues in diagnostic accuracy and prolonged detection times. OBJECTIVES: This study aims to introduce a multispectral imaging (MSI)-based method for the early screening and detection of skin surface lesions. By capturing image data at multiple wavelengths, MSI can detect subtle spectral variations in tissues, significantly enhancing the differentiation of various skin conditions. METHODS: The proposed method utilizes a pixel-level mosaic imaging spectrometer to capture multispectral images of lesions, followed by reflectance calibration and standardization. Regions of interest were manually extracted, and the spectral data were subsequently exported for analysis. An improved one-dimensional convolutional neural network is then employed to train and classify the data. RESULTS: The new method achieves an accuracy of 96.82 % on the test set, demonstrating its efficacy. CONCLUSION: This multispectral imaging approach provides a non-contact and non-invasive method for early screening, effectively addressing the subjective identification of lesions by dermatologists and the prolonged detection times associated with conventional methods. It offers enhanced diagnostic accuracy for a variety of skin lesions, suggesting new avenues for dermatological diagnostics.
Subject(s)
Deep Learning , Keratosis, Seborrheic , Skin Diseases , Humans , Skin Diseases/diagnosis , Skin Diseases/diagnostic imaging , Keratosis, Seborrheic/diagnosis , Keratosis, Seborrheic/diagnostic imaging , Psoriasis/diagnostic imaging , Psoriasis/diagnosis , Dermoscopy/methods , Warts/diagnostic imaging , Warts/diagnosis , Nevus, Pigmented/diagnosis , Nevus, Pigmented/diagnostic imaging , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/diagnosis , Early DiagnosisABSTRACT
Psoriasis (PsO) is a prevalent chronic inflammatory skin disease. It is a complex condition that is affected by environmental and hereditary variables. Numerous pathogens, including viruses, bacteria, and even fungi, have been linked to PsO. One of the mechanisms that clears infections is autophagy. The mechanism by which a cell feeds itself is called autophagy by reusing cytoplasmic components in the lysosome. The autophagy-related (ATG) proteins are essential components of the system that control the strictly regulated process of autophagy. Among these 41 proteins, ATG5 is one that is required in order for autophagic vesicles to develop. This research aimed to compare ATG5 levels in serum among those suffering from psoriasis vulgaris and healthy controls. This cross-sectional research was carried out on 45 individuals with vulgaris psoriasis and 45 healthy, sex and age-matched control subjects. All participants underwent a clinical examination, a laboratory investigation, and a history taking, including lipid profiles and serum ATG5. The mean age of the control and PsO were 40.6 ± 9.6, and 43.7 ± 9.3 years respectively. The mean total PASI score was 13.9 ± 8.9, with a median of 11.7 (8.8). According to the PASI score, about 38% (n = 17) had mild disease (PASI < 10), and about 62% (n = 28) had moderate/severe disease (PASI ≥ 10). There was a significantly higher median (IQR) (25th-75th) ATG5 level in PsO 206 (97) (145-242) ng/ml than in the control 147 (98) (111-209) ng/ml (p = 0.002). An insignificant higher median level (IQR) was observed in PsO with mild disease 207(95) compared with those with moderate/severe disease 183(98.5) (p = 0.057). Dissimilarly, the median (IQR) ATG5 level was significantly lower in PsO individuals with metabolic syndrome 170(72) compared with those without 207(104) (p = 0.044). Four predictors were identified following sex and age adjustments, in the final linear regression model: PASI score, triglyceride, High-Density Lipoprotein, and presence of metabolic syndrome. There can be a connection between autophagy as measured by ATG5 and psoriasis vulgaris. ATG5 was elevated in the serum of individuals with psoriasis vulgaris. However, it decreased in patients with metabolic syndrome. No relation was found between serum ATG5 and PASI score. Psoriasis vulgaris patients may benefit from using an autophagy enhancer as a potential treatment target.
Subject(s)
Autophagy-Related Protein 5 , Autophagy , Biomarkers , Psoriasis , Humans , Psoriasis/blood , Psoriasis/diagnosis , Psoriasis/immunology , Psoriasis/pathology , Autophagy-Related Protein 5/blood , Autophagy-Related Protein 5/genetics , Autophagy-Related Protein 5/metabolism , Cross-Sectional Studies , Female , Adult , Male , Middle Aged , Biomarkers/blood , Severity of Illness Index , Case-Control StudiesABSTRACT
BACKGROUND: While extensive research has provided a wealth of information on psoriasis in general, there remains a critical gap in understanding the unique characteristics of psoriasis in special body areas, such as the scalp, nails, palms, and genitals. OBJECTIVE: To investigate the characterization and treatment of psoriasis patients in special body areas. METHODS: The study was a retrospective analysis of patients with psoriasis enrolled in the Psoriasis Standardized Diagnosis and Treatment Center Project between January 2020 and September 2021. RESULTS: The study encompassed 346 patients, 81% of them had psoriasis in at least two special body areas, with the nails as the most common area. Patients with genital psoriasis reported higher Dermatology Life Quality Index (DLQI) scores. A higher propensity for scalp and palmoplantar psoriasis was noted in patients with genital psoriasis. The proportion of patients treated with biologics rose, as the number of specific areas involved increased. CONCLUSIONS: Patients with genital psoriasis are more likely to have scalp and palmoplantar psoriasis. This study highlights the significant escalation in the proportion of biologics when the involvement of special body areas was ≥2.
Subject(s)
Psoriasis , Humans , Psoriasis/diagnosis , Psoriasis/drug therapy , Retrospective Studies , Female , Male , Middle Aged , Adult , China , Quality of Life , Scalp Dermatoses/diagnosis , Biological Products/therapeutic use , Severity of Illness Index , Dermatologic Agents/therapeutic use , Aged , East Asian PeopleSubject(s)
Biomarkers , Disease Progression , Psoriasis , Adult , Female , Humans , Male , Middle Aged , Biomarkers/metabolism , Psoriasis/diagnosis , Psoriasis/immunology , Psoriasis/pathologyABSTRACT
Increased intestinal permeability and gut dysbiosis are important factors in the pathophysiology of psoriasis and its associated conditions. Claudin-3 is a protein that is found in tight junctions and may be used to assess the integrity of the gut barrier. The aim of this study was to investigate serum concentration of Claudin- 3 (CLDN3) in patients with psoriasis. Exploring its possible relations with patients' demographic, clinical and laboratory findings was another objective. Fifty psoriatic patients and thirty-five age- and sex-matched healthy volunteers served as the study's control group in this case-control, hospital-based research. The amount of serum CLDN3 was determined by means of an enzyme-linked immunosorbent test (ELISA). Concentration of serum CLDN3 was found to be significantly higher in patients with psoriasis. (p = 0.002). There was no statistically significant correlation between CLDN3 and patient's clinical & laboratory variables. We demonstrated that gut permeability is dysfunctional in patients with psoriasis as indicated by reduction of serum CLDN3. Further investigations are needed to determine whether modulation of gut barrier may represent a new therapeutic approach for psoriasis.
Subject(s)
Biomarkers , Claudin-3 , Psoriasis , Skin , Adult , Female , Humans , Male , Middle Aged , Young Adult , Biomarkers/blood , Case-Control Studies , Claudin-3/blood , Dysbiosis/diagnosis , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Permeability , Psoriasis/blood , Psoriasis/diagnosis , Skin/pathology , Tight Junctions/metabolismABSTRACT
BACKGROUND: Numerous studies have linked the inflammatory pathway in psoriasis and metabolic disease, while no specific marker defined it. It is worth exploring the association of ß2-microglobulin (ß2M) in psoriasis severity and comorbidities. OBJECTIVES: To investigate the correlation between blood ß2M level and psoriasis severity, to explore the inflammatory factors influencing the occurrence of psoriasis comorbidities such as arthritis, diabetes, and hypertension. METHODS: Ninety-seven psoriasis patients were analyzed in the cohort retrospective study during 12 weeks. RESULTS: Significantly higher levels of blood ß2M and ESR were observed in the group that patients' PASI ≥10 than in the group that PASI <10. Blood ß2M level had strong significantly positive correlations with the PASI in Pearson's correlation analysis. In the model that systemic inflammatory factors to find psoriasis comorbidity risk factors, logistic regression analysis showed that blood ß2M level was the significant risk factor associated with diabetes and hypertension. High-sensitivity C-reactive protein (hsCRP) was the significant risk factor associated with arthritis. CONCLUSIONS: Patients with a severer psoriasis tended to have higher blood ß2M levels and severer inflammatory state. In the systemic inflammation indexes, the level of blood ß2M affected the risk of hypertension and diabetes, and hsCRP affected the risk of arthritis in patients with psoriasis.